deaths from glp-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Cardiovascular and mortality outcomes with

National Health and Nutrition Examination Survey (NHANES) data showed rates rising from roughly 30% in 19992000 to over 42% by 20172020, with severe obesity increasing even faster

Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population

By injecting a small dose of prescribed Semaglutide GLP-1 into the upper arm, thigh, or abdomen, patients have reported themselves better at resisting their cravings, feeling satiated for longer periods of time, and that their energy levels feel more stable throughout the day

Reduces inflammation and cholesterol GLP-1 medications decrease inflammationa key driver of heart disease